The Thesis
PanicFade v4 is a contrarian mean-reversion strategy built on a simple, literature-backed premise: markets overreact to bad news. When a negative headline shock (sentiment below -0.4) hits a name that is already oversold — RSI14 under 35 and trading below its SMA20 — the strategy leans in and sizes into the panic, betting on reversion toward fundamentals. It exits when the bounce arrives (RSI14 back above 50 or price reclaiming the SMA20) and hard-stops on fresh lows under continued negativity, treating that as a genuine fundamental break rather than noise.
The design cites recent sentiment-asymmetry research (arXiv:2509.11970, 2025) and the broader negative-media overreaction/reversion literature. Its universe is 24 mega-cap and large-cap names — AAPL, MSFT, NVDA, JPM, JNJ, XOM and peers — where liquidity is deep and "panic" is more likely to be sentiment than solvency.
Validation: The Strong Part
This is where PanicFade v4 earns attention. Across four walk-forward folds spanning September 2021 to August 2026, all four were positive — no small feat for a strategy that only trades during stress. Out-of-sample return came in at 21.7% with an OOS Sharpe of 2.44. The probabilistic Sharpe ratio sits at a commanding 0.985, and even the deflated Sharpe ratio — which penalises the 27 configurations trialled during development — remains positive at 0.56. That combination suggests the edge is more than curve-fitting.
The fold trajectory is encouraging but worth reading carefully: returns climbed from a barely-positive 1.6% (Sharpe 0.19) in the turbulent 2021–22 fold to 21.7% (Sharpe 2.44) in the most recent one. The improvement is real, but a single fold carrying an outsized Sharpe should temper expectations — 2.44 is not a number to annualise into the future.
The Backtest, In Full
Over 1,233 trading days and 530 trades, the full backtest returned 37.93% (final equity $13,793 on $10k), with a 62.88% win rate and a manageable 9.3% max drawdown. Sharpe was 0.96. The headline return flatters a more sober CAGR of just 6.79% — respectable for a low-drawdown contrarian sleeve, but not spectacular. Turnover is the eyebrow-raiser at 5,807%, meaning fees and slippage matter a great deal; the model booked $530 in fees, and in a higher-cost regime that edge would erode faster.
Recent Activity: Silence
Live since deployment, PanicFade v4 has done precisely nothing this past week. Every scheduled run from 14 to 21 August executed zero trades and rejected zero candidates, holding cash flat at $10,000. This is a feature, not a bug — the strategy only fires when genuine panic meets oversold conditions, and a calm, grinding-higher tape offers no fuel. But it is also the strategy's central risk: it is structurally dependent on volatility events, can sit idle for long stretches, and delivers its returns lumpily.
Verdict
PanicFade v4 is one of the better-validated strategies in the lab — genuinely out-of-sample robust, low-drawdown, and grounded in real research. The caveats are equally clear: modest CAGR, punishing turnover, and a payoff profile that only shows up when markets get scared. A patient, opportunistic sleeve — not a workhorse.